Articles

Glycosylation homogeneity and pattern can be increase with cell line engineering and bioprocess optimization. But, these can be time-consuming and might compromise yield. In vitro glycoengineering can solve these problems and is independent from the cell line and the bioprocess used.


In vitro glycoengineering – Suitability for BioPharma manufacturing

It can be challenging to define suitable operational definitions for volume-dependent parameters for upstream bioprocesses. In this work, we perform robust DoE mass-transfer characterization of the BIOne SUB and utilize a kʟa criterion to successfully define such parameters for a HEK-293 process. 

Upstream Process Development with a kʟa Criterion

Protect the integrity of your data with technologies that meet regulatory requirements for secure, accurate data capture and record-keeping.

Data Integrity in Pharmaceutical Labs

In 2019, G-CON provided the cleanroom solution for GenCure’s new multi-product cell therapy facility. The new facility expands GenCure’s manufacturing capabilities, providing state-of-the-art manufacturing services to therapeutic developers.

Prefabricated Cleanrooms for Cell Therapy Manufacturing

Approaches for Protein Glycosylation Engineering: The Why and the How 

High-density cell banking accelerates the upstream process by providing concentrated cells to jumpstart a production run. This intensification eliminates many laborious and risky steps used in most labs


Fluoropolymer for Efficient High-Density Cell Banking

Featured Resources for Oligonucleotides Separations

Featured Resources for Glycan Analysis

Cerba Research initiated custom kit building and distribution for an infectious disease study, during the COVID-19 pandemic, in 10 days. A typical timeline is 8 weeks.

Ten-Day Lab Startup in a Pandemic

Bridging Anti-CHO HCP Antibodies from Two 3rd Generation Cygnus CHO HCP ELISA Kits by AAE-MS

All Whitepapers